Dr. Allen Chao Joins NexBio, Inc. Board of Directors

Dr. Allen Chao Joins NexBio, Inc. Board of Directors

SAN DIEGO, Jan. 19 /PRNewswire/ -- NexBio, Inc. announced today the appointment of Allen Chao, Ph.D., Founder, Chairman and former CEO of Watson Pharmaceuticals, to its Board of Directors as an independent director. 

"We are very excited to have Allen on board, and we greatly value Allen's unparalleled record of entrepreneurship and company-building as one of the most successful biopharmaceutical executives in the world," said Mang Yu, Ph.D., NexBio's Chairman and CEO. "Allen is a visionary pharmaceutical executive who is especially skillful in commercialization of biopharmaceutical products. We know his wisdom, commercial focus and vision will be invaluable as NexBio grows into a fully integrated biopharmaceutical company. We look forward to his guidance on all strategically important issues in growing the company."

 

ABOUT NEXBIO

 

For more information about NexBio, Inc., please visit http://www.nexbio.com

DISCLOSURE NOTICE:

 


CONTACT: David Wurtman, M.D., M.B.A., VP, Corporate Development of NexBio,
Inc., +1-858-452-2631, [email protected]

Web site: http://www.nexbio.com/

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.